BK

Beata Klein

Partner at Creandum

Germany

Invests in

Stages:

Locations:

  • Min Investment:

    $230,000.00
  • Max Investment:

    $9,300,000.00
  • Target Investment:

    $4,765,000.00

Work Experience

2020

  • Partner

    2020

    Creandum is one of the leading early stage VCs and have invested in over 120 companies, of which 20 are unicorns today, including Spotify, iZettle, Klarna, Factorial, Pleo, Kry, Trade Republic, Neo4j, Bolt, Taxfix, Virta Health, Kahoot and many more. Every 6th investment of the Creandum funds reached 1 BUSD valuation.

  • Board Member

    2023

    Seed round

2022 - 2025

  • Advisory Board

    2022 - 2025

    Pre-seed round

2022 - 2023

  • Advisory Board

    2022 - 2023

    Series A round

2020 - 2022

  • Board Observer

    2020 - 2022

    Joined the board after Series A

2018 - 2019

  • Venture Co-Founder & CEO

    2018 - 2019

    Co-founded and built one of the ventures at fram^ group, an online tutoring platform inspired by VIPKid and Zhangmen. Shipped the MVP, kicked off GTM, built the team, and grew it from zero to early revenue with solid initial traction.

2017 - 2018

  • Executive Trainee / Chief of Staff to CEO

    2017 - 2018

    Worked closely with the CEO of Tele2 Sweden in a Chief of Staff capacity. Supporting board-level matters, driving key operational initiatives, and contributing to high-priority projects, including the merger between Tele2 and Com Hem.

2016 - 2016

  • Summer Intern

    2016 - 2016

    Part of the online sales team, where I built a data-driven model to optimize SKU distribution across regions, improving inventory allocation and sales performance.

2016 - 2016

  • Corporate Finance Intern

    2016 - 2016

    Interned in the Corporate Finance team at Danske Bank, one of the top financial institutions in the Nordics. Supported several transactions through market research, financial modeling, and client material preparation.

2014 - 2015

  • Analyst

    2014 - 2015

    Worked part-time during university at Mendus, a biotech company developing off-the-shelf, cell-based immunotherapies for cancer. Did market research around new treatment areas and supported with IR and PR.